Redefining Value in Transthyretin Amyloidosis Cardiomyopathy Care: Innovations in Diagnosis, Treatment, and Access

Program Description

Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease caused by the misfolding of transthyretin proteins into amyloid fibrils that deposit in the heart, leading to restrictive cardiomyopathy and heart failure. Despite its severity, ATTR-CM is frequently underdiagnosed or delayed as symptoms often overlap with more common conditions. This session is designed to equip managed care professionals and pharmacists with the clinical and economic insights necessary to resolve diagnostic and treatment delays in ATTR-CM. Through a review of current therapies, including established TTR stabilizers, as well as the expanding role of TTR gene silencers and other investigational agents, expert speakers will explore critical considerations in treatment sequencing, the interpretation of serum TTR as a biomarker, and the application of health economic data to inform sustainable formulary decisions. By highlighting the pivotal role of the managed care pharmacist in multidisciplinary teams, this program aims to optimize patient-centered access, improve therapy adherence, and leverage emerging diagnostic tools to reduce the systemic and economic burden of ATTR-CM.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify key symptoms and common diagnostic pitfalls for transthyretin amyloidosis cardiomyopathy (ATTR-CM) and their impact on timely diagnosis and optimal resource use.
• Explain the comparative safety, efficacy, cost considerations, and mechanisms of action for available and emerging therapies for ATTR-CM.
• Apply team-based care models and health economic data to optimize managed care contributions to patient-centered access, therapy adherence, and sustainable formulary decisions for ATTR-CM.